Cargando…

Neurovascular ageing: transcriptomic readout and implications on therapeutic targeting in Alzheimer's disease

Detalles Bibliográficos
Autores principales:	Li, Zhongqi, Ip, Bonaventure, Mok, Vincent C. T., Ko, Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374564/ https://www.ncbi.nlm.nih.gov/pubmed/33907022 http://dx.doi.org/10.4103/1673-5374.313042

Ejemplares similares

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner
por: Li, Zhongqi, et al.
Publicado: (2021)

Neurovascular unit permeability in neuroinflammatory diseases: a common pathologic and therapeutic target?
por: Monsour, Molly, et al.
Publicado: (2022)

Repurposing ibrutinib: therapeutic effects and implications for translational approaches in Alzheimer’s disease
por: Lee, Hyun-ju, et al.
Publicado: (2023)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

The implication of neurovascular unit signaling in controlling the subtle balance between injury and repair following ischemic stroke
por: ElAli, Ayman
Publicado: (2016)

CD34(+) progenitor cells as diagnostic and therapeutic targets in Alzheimer’s disease
por: Romaus-Sanjurjo, Daniel, et al.
Publicado: (2022)

Is EAAT2 a potential therapeutic intervention target for Alzheimer’s disease?
por: Wood, Oliver WG, et al.
Publicado: (2023)

Targeting calcium signaling in Alzheimer’s disease: challenges and promising therapeutic avenues
por: Song, LinLin, et al.
Publicado: (2023)

Diabetic retinopathy: neurovascular disease requiring neuroprotective and regenerative therapies
por: Oshitari, Toshiyuki
Publicado: (2021)

The role of dietary nitrate supplementation in neurovascular function
por: Horiuchi, Masahiro, et al.
Publicado: (2020)

Accelerated aging-related transcriptome alterations in neurovascular unit cells in the brain of Alzheimer’s disease
por: Zhao, Yan, et al.
Publicado: (2022)

Neurovascular and neurometabolic derailment in aging and Alzheimer's disease
por: Lourenço, Cátia F., et al.
Publicado: (2015)

On-chip physiological mimicry of neurovascular unit: challenges and perspectives
por: Ahn, Song Ih, et al.
Publicado: (2023)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target
por: Govindpani, Karan, et al.
Publicado: (2019)

Next generation therapeutics for Alzheimer's disease
por: Bredesen, Dale E, et al.
Publicado: (2013)

Therapeutic implications of advanced age at time of spinal cord injury
por: Stewart, Andrew N., et al.
Publicado: (2019)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Neurovascular coupling mechanisms in health and neurovascular uncoupling in Alzheimer’s disease
por: Zhu, Winston M, et al.
Publicado: (2022)

Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease
por: Grammas, Paula
Publicado: (2011)

Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
por: Weninger, Stacie, et al.
Publicado: (2020)

Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease
por: Monteiro, Kadja Luana Chagas, et al.
Publicado: (2020)

New unexpected role for Wolfram Syndrome protein WFS1: a novel therapeutic target for Alzheimer’s disease?
por: Chen, Shuo, et al.
Publicado: (2022)

Implication of salivary lactoferrin and periodontal-mediated infections in Alzheimer’s disease
por: Municio, Cristina, et al.
Publicado: (2023)

Melastatin-related transient receptor potential 2 channel in Aβ(42)-induced neuroinflammation: implications to Alzheimer’s disease mechanism and development of therapeutics
por: Wei, Linyu, et al.
Publicado: (2018)

On the horizon—the value and promise of the global pipeline of Alzheimer's disease therapeutics
por: Cole, Michael A., et al.
Publicado: (2020)

Estrogens still represent an attractive therapeutic approach for Alzheimer’s disease
por: Tamagno, Elena, et al.
Publicado: (2021)

Diagnostic and therapeutic potential of exosomal miRNAs in Alzheimer’s disease
por: Manna, Ida, et al.
Publicado: (2021)

Potential contributions of trace amines in Alzheimer’s disease and therapeutic prospects
por: Dhakal, Sudip, et al.
Publicado: (2020)

TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease
por: Hicks, David A.
Publicado: (2020)

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society
por: Erickson, Claire M., et al.
Publicado: (2022)

The Neurovascular Unit Dysfunction in Alzheimer’s Disease
por: Soto-Rojas, Luis O., et al.
Publicado: (2021)

The therapeutic potential of mesenchymal stem cells in Alzheimer's disease: converging mechanisms
por: Turgeman, Gadi
Publicado: (2015)

Using Plants as a Source of Potential Therapeutics for the Treatment of Alzheimer’s Disease
por: Maher, Pamela A.
Publicado: (2020)

Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
por: Rabinovici, Gil D., et al.
Publicado: (2016)

Mixed pathologies and neural reserve: Implications of complexity for Alzheimer disease drug discovery
por: Bennett, David A.
Publicado: (2017)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

Targeting the guanine-based purinergic system in Alzheimer's disease
por: Lanznaster, Débora, et al.
Publicado: (2017)

Dual targeting nano-approaches for Alzheimer's disease etiology
por: Hettiarachchi, Sajini D., et al.
Publicado: (2020)

Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease
por: Sumbria, Rachita K.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hl35oqaqlgntcgqsnh65ocph7r